繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

2025-06-04 20:30

SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: Truist Securities MedTech Conference. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 160 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. 

Investor Contact: Saqib Iqbal, investors@si-bone.com


風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。